

1/22/93

#12

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER RB541174953

DATE OF DEPOSIT MARCH 10, 1993

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE

"EXPRESS MAIL POST OFFICE TO ADDRESSEE"

SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED

ABOVE AND IS ADDRESSED TO THE COMMISSIONER

OF PATENTS AND TRADEMARKS, WASHINGTON, D.C. 20231.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT) PAUL DARDES

SIGNATURE Paul Dardes



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Extension for U.S. Patent No. 4,721,723

Issued: January 26, 1988

To: Roger D. Barnes et al

For: Anti-depressant Crystalline Paroxetine Hydrochloride

March 10, 1993

Office of the Assistant Commissioner
for Patents and Trademarks

Box Patent Extension

Washington, D.C. 20231

Attention: Mr. Charles Van Horn

Re: SmithKline Beecham Corporation (a sister corporation of
Beecham Group p.l.c.)
Deposit Account No. 19-2570
U.S. Patent No. 4,721,723

Sir:

Per my secretary's conversation with Mr. Jerry Dost on March 9, 1993, enclosed are five copies of the application for extension of the term of U.S. Patent 4,721,723 under 35 U.S.C. 156 as mailed via Express Mail No. RB541174964 on February 22, 1993. A copy of the Express Mail Receipt and the returned postcard showing the PTO Mailroom receipt date of February 22, 1993 is also attached.

DF11304 03/22/93 4721723


19-2570 110 111 1,000.00CH

Mr. Eric Burns of the PTO's Mailroom orally confirmed with my secretary that the Express Mail package had been received. Mr. Dost orally advised my secretary that he was informed by the supervisor of the Mailroom that the package was sent via internal mail to your office.

Please let me know if further information is required.

Respectfully submitted,

BEECHAM GROUP, p.l.c.

By: 
Edward T. Lentz
Attorney for Applicant
Registration No. 30,191

SmithKline Beecham Corporation
Corporate Patents - U.S. - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
215-270-5065

n:\etl\newsub.doc
Enclosures (5)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re: U.S. Patent 4,721,723
Issued: January 16, 1993
To: Roger D. Barnes et al
For: Anti-depressant Crystalline Paroxetine Hydrochloride

February 22, 1993

Commissioner of Patents and Trademarks
Box Patent Extension
Washington, D.C. 20231

Re: Deposit Account No. 19-2570
SmithKline Beecham Corporation
(a sister corporation of Beecham Group p.l.c.)
U.S. Patent No. 4,721,723


Sir:

Transmitted herewith is an original application for extension of patent term under 35 U.S.C. 156 with regard to U.S. Patent No. 4,721,723 and one photocopy thereof.

Please charge my Deposit Account No. 19-2570 in the amount of \$1,000.00. The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Account No. 19-2570. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

BEECHAM GROUP p.l.c.

By: 
Edward T. Lentz
Attorney for Applicant
Registration No. 30,191

SmithKline Beecham Corporation
Corp. Patents-U.S. - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Tel: 215-270-5040

Drug/Compound.....: PAXIL
Application No.....: NDA-20031
Date Subm/Issue....: 10/15/92
Description.....: SUBMITTED THE SUBMISSION HISTORY OF
NDA-20031 TABLETS.

Drug/Compound.....: PAXIL
Application No.....: NDA-20031
Date Subm/Issue....: 11/04/92
Description.....: SUBMITTED FINAL SAFETY UPDATE. THIS
REPORT IS AN ABBREVIATED UPDATE TO THE
PAROXETINE WORLDWIDE SAFETY DATABASE.
DEATHS AND SERIOUS EVENTS REPORTED
SPONTANEOUSLY FROM THE MARKETED USE OF
PAROXETINE IN THE UK, SWEDEN, HOLLAND
AND SOUTH AFRICA ARE PRESENTED.

Drug/Compound.....: PAXIL
Application No.....: NDA-20031
Date Subm/Issue....: 11/12/92
Description.....: SUBMITTED THE WORLDWIDE LITERATURE
REVIEW ON PAXIL TABLETS AND THE CURRENT
STATUS OF MARKETING OUTSIDE THE UNITED
STATES INCLUDING COPIES OF LABELING FOR
EACH COUNTRY WHERE IT IS MARKETED.

Drug/Compound.....: PAXIL
Application No.....: NDA-20031
Date Subm/Issue....: 12/01/92
Description.....: PER FDA REQUEST 08/31/92 AND 09/04/92,
SUBMITTED ADDITIONAL STABILITY DATA
CONCERNING TABLETS PRODUCED BY THE
ORIGINAL NDA PROCESS. ALSO ENCLOSED
IS CMC DATA CONCERNING THE PRODUCTION
OF TABLETS BY THE ORIGINAL NDA PROCESS
AS WELL AS THE REVISED PROCESS.

Drug/Compound.....: PAXIL
Application No.....: NDA-20031
Date Subm/Issue....: 12/02/92
Description.....: SUBMITTED FOUR COPIES OF THE REVISED
SAMPLE PACKAGE LAYOUT AND DRAFT SAMPLE
OUTER CARTON LABELING.

Drug/Compound.....: PAXIL
Application No.....: NDA-20031
Date Subm/Issue....: 12/7/92
Description.....: SUBMITTED TWO COPIES OF LAUNCH PROMOTIONAL
MATERIALS FOR REVIEW AND TWO COPIES OF
CURRENT DRAFT LABELING.

POWER OF ATTORNEY

The undersigned Beecham Group p.l.c., formerly Beecham Group Limited, a corporation of England hereby authorizes in the name and on behalf of Beecham Group p.l.c., Edward T. Lentz, a patent attorney registered with the U.S. Patent and Trademark Office, Registration No. 30,191 whose business address is SmithKline Beecham Corporation, Corporate Patents - U.S., UW2220, P.O. Box 1539, King of Prussia, Pa. 19406-0939, USA to act on behalf of Beecham Group p.l.c. in all patent matters including the power to execute (or revoke) powers of attorney, disclaimers, patent term extensions, concessions of priority, abandonments, assents to filing reissue applications, petitions to make special, applications to correct inventorship, patent assignments, pleadings, interrogatories, oppositions, affidavits of use, and petitions for reexamination, and to execute all other papers and take all such actions as he may deem necessary or appropriate in order to file, prosecute, abandon, terminate, extend or transfer applications for patents and other industrial property rights in the United States and countries foreign thereto, and to defend, assert, and maintain such property rights in full force and effect.

Executed as of the 17th day of February, 1993.

BEECHAM GROUP p.l.c.



David Roberts
As Attorney for and on behalf of
the said Beecham Group p.l.c.

RB541174964

POST OFFICE
TO ADDRESSEE

ORIGIN	Date In	Postage
Post Office 19428	Time In 12:14	1395
Zip Code	Initials of Receiving Clerk B1	Weight 1.1 oz.
ACCEPTANCE		
<input checked="" type="checkbox"/> Next Day Delivery or <input type="checkbox"/> Second Day Delivery <input checked="" type="checkbox"/> By 12 Noon or <input type="checkbox"/> By 3:00 P.M. <input type="checkbox"/> Express Mail Military Service <input type="checkbox"/> International Express Mail Country Code		
Express Mail Corporate Account No. 19428-00000 Federal Agency Account No. 19428-00000		
FROM: SMITH KLINE BEECHAM CORPORATE PATENTS US DM 2220 P.O. BOX 1588 KING OF PRUSSIA PA 19406-0989		



SEE REVERSE FOR SERVICE GUARANTEE,
INSURANCE COVERAGE AND CLAIMS.
THANK YOU FOR CHOOSING EXPRESS
MAIL SERVICE.



EXPRESS MAIL

NEXT DAY SERVICE

I wish delivery to be made without obtaining the signature of the addressee or the addressee's agent (if in the judgment of the delivery employee, the article can be left in a secure location) and I authorize the delivery employee to sign that the shipment has been delivered and understand that the signature of the delivery employee will constitute valid proof of delivery.

SIGNED:

CUSTOMER RECEIPT

Waiver of
Signature
and Indemnity
(Domestic Only)

TO:

Telephone Number:

COMMISSIONER OF PATENTS
& TRADEMARKS
BOX PATENT & TRADEMARK EXTENSION
WASHINGTON, DC 20231-0901

Application for:
Extension of Patent Term for U.S. Patent No. 4,721,723
Certification, Declaration and Power of Attorney
enclosed.

Attachments A, B and C enclosed.

Mailed via Express Mail No. RB541174964.

RECEIVED BY THE PATENT AND TRADEMARK OFFICE





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 4,721,723

Issued: January 26, 1988

To: Roger D. Barnes et al

For: Anti-depressant Crystalline Paroxetine Hydrochloride

February 22, 1993

Commissioner of Patents and Trademarks
Box Patent Extension
Washington, D.C. 20231

CERTIFICATION

The undersigned hereby certifies that the attached photocopy is an exact duplicate of the application for extension of the term of U.S. Patent 4,721,723 under 35 U.S.C. 156, including its attachments and supporting papers, mailed to the U.S. Patent and Trademark Office herewith on this date.

Date: February 22, 1993

Edward T. Lentz

n:\et\extenpat.doc